Annual Drug Patent Expiration for TRUMEQ
Triumeq is a drug marketed by Viiv Healthcare and is included in two NDAs. It is available from a single supplier. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for TRUMEQ.
This drug has one hundred twenty four patent family members in thirty three countries.
The generic ingredient in TRUMEQ is abacavir sulfate; dolutegravir sodium; lamivudine. One registered supplier for this compound. Additional details are available on abacavir sulfate; dolutegravir sodium; lamivudine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Copyright © DrugPatentWatch. Originally published in New patent for the drug Viiv Hlthcare TRIUMEQ